KLF17 and lung cancer: Silencing KLF17 might reduce Smad3- DNA complex formation as a novel model for regulating the TGF-β/SMAD pathway to inhibit the growth of A549 or PC-9 cells and to insight into anti-metastatic function [86,126], suggested that these oncogenic KLFs might be promising molecular target or combining with immunotherapy for lung cancer therapy [127,128].